Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Wappingers Falls, New YorkAges 18 years+ - NCT05451303Recruiting
Testing for oral and throat cancer risk with a mouth test
This trial studies how well an at-home or clinic mouth test (OralViome Cancer Testing System) can detect signs of risk for oral or throat cancer. You may benefit by getting cancer-risk testing if you are considered high risk, though results will guide whether further evaluation is needed.
New York, New YorkAges 18 years+ - NCT05562778Recruiting
Chatbot helps you complete hereditary cancer genetic risk testing
This study tests whether a chatbot can help people complete hereditary cancer genetic risk assessment before a gynecology new-patient visit. It may help you understand and organize next steps for genetic testing, if needed.
Brooklyn, New YorkAges 18 years+ - NCT05590949Recruiting
Study of bone problems after stopping breast cancer medicines
This observational study looks at bone complications in post-menopausal women with breast cancer after stopping denosumab and an aromatase inhibitor. It may help doctors better understand who is at risk for bone weakening and fractures after these medicines are stopped.
Commack, New YorkAges 18 years+ - NCT05607108RecruitingPhase 2
Study drug for advanced lung cancer with a specific genetic change
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Uniondale, New YorkAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Batavia, New YorkAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Elmira, New YorkAges 18 years+ - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Commack, New YorkAges 18 years+ - NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Buffalo, New YorkAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
East Syracuse, New YorkAges 18–130 - NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Mineola, New YorkAges 18 years+ - NCT05789485RecruitingPhase 2
Exercise program to reduce treatment side effects in GI cancer
This trial studies whether a structured exercise plan can lessen side effects from chemotherapy in people with colorectal or stomach/esophagus solid tumors. If you’re about to start chemotherapy, the study will check whether exercising helps you feel and function better during treatment.
Commack, New YorkAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Brooklyn, New YorkAges 18 years+ - NCT06007924RecruitingPhase 2
Study of avutometinib and defactinib for thyroid cancer
This trial tests two oral drugs (avutometinib and defactinib) for people with certain types of advanced thyroid cancer that have specific genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
Rockville Centre, New YorkAges 18 years+ - NCT06023576RecruitingPhase 2
Blood pressure control during breast cancer chemo
This study tests whether careful blood pressure management can help protect the heart during certain types of chemotherapy (anthracyclines) for breast cancer. Participants will use a smart blood pressure device and may also do an exercise test.
Commack, New YorkAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Cooperstown, New YorkAges 18 minutes+ - NCT06033248Recruiting
Urine test for early lung cancer detection
This study is testing if urine samples can help detect lung cancer early. You might help by providing a urine sample—either if you have early-stage lung cancer, have a suspicious lung nodule, or don’t have lung cancer at all.
Commack, New YorkAges 18–90 - NCT06083844RecruitingPhase 2
Keytruda + Avastin + chemo for ovarian cancer with minimal remaining disease
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
New York, New YorkAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Uniondale, New YorkAges 18 years+ - NCT06110793RecruitingPhase 1/Phase 2
Study of lenvatinib, pembrolizumab, and fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) for people with a certain type of advanced breast cancer that has stopped responding to previous hormone therapy. The goal is to see if this new combination can help shrink or control the cancer.
Uniondale, New YorkAges 18 years+ - NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Uniondale, New YorkAges 18 years+ - NCT06127979Recruiting
Hormone therapy before surgery for breast cancer
This study looks at how a hormone-blocking medicine (endocrine therapy) given before surgery affects a marker called Ki67 in your breast cancer cells. The goal is to see if the medicine can slow the growth of the cancer, which may help doctors choose the best treatment for you.
New York, New YorkAges 18 years+ - NCT06130280RecruitingPhase 2
MRI-guided radiation for liver tumors from colorectal cancer
This trial tests a single, high-dose radiation treatment (SBRT) guided by MRI for people with colorectal cancer that has spread to the liver. The goal is to see if this precise, one-time treatment can effectively control liver tumors while protecting nearby organs.
New York, New YorkAges 18 years+ - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
New York, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 16 studies
- Memorial Sloan Kettering Commack · 13 studies
- Memorial Sloan Kettering Nassau · 13 studies
- Memorial Sloan Kettering Westchester · 10 studies
- University of Rochester · 4 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 3 studies
- Montefiore Medical Center · 3 studies
- Highland Hospital · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.